Gadolinium-based contrast agents and NSF: Evidence from animal experience

Journal of Magnetic Resonance Imaging

Volumn 30, Issue 6, 2009, Pages 1268-1276

  Sieber, Martin A ^a   Steger Hartmann, Thomas ^a   Lengsfeld, Philipp ^a   Pietsch, Hubertus ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Gadolinium; Gadolinium based contrast agents; Magnetic resonance imaging; Nephrogenic systemic fibrosis; Rodent models

Indexed keywords

CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOVERSETAMIDE; ZINC;

AREA UNDER THE CURVE; CONFERENCE PAPER; CONTRAST ENHANCEMENT; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TISSUE LEVEL; FIBROBLAST; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SKIN DEFECT; TOXICITY TESTING;

ANIMALS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; EVIDENCE-BASED MEDICINE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; NEPHROGENIC FIBROSING DERMOPATHY; RATS;

EID: 73649097259     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21971     Document Type: Conference Paper

References (53)

1. Morcos SK, Thomsen HS. Nephrogenic systemic fibrosis: more questions and some answers. Nephron Clin Pract 2008;110:c24-31; discussion c32.
2. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1001.
3. Kuhlmann U, Walb D, Luft FC. Nephrologie. Stuttgart: Georg Thieme; 2003.
4. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008;66:230-234.
5. Bucala R. Circulating fibrocytes: cellular basis for NSF. J Am Coll Radiol 2008;5:36-39.
6. Lewis KG, Lester BW, Pan TD, Robinson-Bostom L. Nephrogenic fibrosing dermopathy and calciphylaxis with pseudoxanthoma elasticum-like changes. J Cutan Pathol 2006;33:695-700.
7. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:3604-3605.
8. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245:168-175.
9. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007;7:2425-2432.
10. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis. Arthritis Rheum 2007;56:3433-3441.
11. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008;43:65-75.
12. Sieber MA, Lengsfeld P, Walter J, et al. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging 2008;27:955-962.
13. Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008;18:2164-2173.
14. Frenzel T, Lengsfeld P, Schirmer H, Hutter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008;43:817-828.
15. Steger-Hartmann T, Raschke M, Riefke B, Pietsch H, Sieber MA, Walter J. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 2009 [Epub ahead of print].
16. Pietsch H, Lengsfeld P, Jost G, Frenzel T, Hutter J, Sieber MA. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. Eur Radiol 2009;19:1417-1424.
17. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 2009;44:226-233.
18. Pietsch H, Pering C, Lengsfeld P, et al. Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study. J Magn Reson Imaging 2009;30:374-383.
19. Thomsen HS, Marckmann P. Extracellular Gd-CA: differences in prevalence of NSF. Eur J Radiol 2008;66:180-183.
20. BfArM. Gadolinium-haltige Kontrastmittel für MRT: Aktualisierter Stand zur Anzahl von Berichten über NSF-Risiko. BfArM; 2008.
21. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991;26:975-979.
22. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502.
23. Grant D, Johnsen H, Juelsrud A, Lovhaug D. Effects of gadolinium contrast agents in naive and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol 2009:1-14.
24. Haylor JL, Dencausse H, Vickers M, Idee JM, Slater D, Morcos SK. Increased skin cellularity following Omniscan in rats with reduced renal function. Eur Radiol 2009;19(Suppl 1):S284.
25. Varani J, Dasilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 2009;44:74-81.
26. Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008;214:584-593.
27. Wermuth PJ, Del Galdo F, Jimenez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009;60:1508-1518.
28. Abraham JL, Thakral C. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol 2008;66:200-207.
29. Distler JH, Akhmetshina A, Schett G, Distler O. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009;48:98-103.
30. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-567.
31. Wilkens KH, Vollmerhaus B, Habermehl H. Band III: Haut und Hautorgane. Lehrbuch der Anatomie der Haustiere. In: Nickel R, Schummer A, Seiferle E, editors. Berlin: Paul Parey; 1991.
32. Travis CC, White RK. Interspecific scaling of toxicity data. Risk Anal 1988;8:119-125.
33. Kimura J, Ishiguchi T, Matsuda J, et al. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. Radiat Med 2005;23:322-326.
34. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev 1987;87:901-927.
35. Tweedle MF, Hagan JJ, Kumar K, Mantha S, Chang CA. Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging 1991;9:409-415.
36. Puttagunta NR, Gibby WA, Smith GT. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest Radiol 1996;31:739-742.
37. Evans CH. Biochemistry of the lanthanides. Biochemistry of elements. In: Frieden E, editor. New York: Plenum; 1989.
38. Ide M, Kuwamura M, Kotani T, Sawamoto O, Yamate J. Effects of gadolinium chloride (GdCl(3)) on the appearance of macrophage populations and fibrogenesis in thioacetamide-induced rat hepatic lesions. J Comp Pathol 2005;133:92-102.
39. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol 2007;80:581-582.
40. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990;8:467-481.
41. Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 1993;28Suppl 1:S28-43.
42. Wible JH Jr, Troup CM, Hynes MR, et al. Toxicological assessment of gadoversetamide injection (OptiMARK), a new contraste-nhancement agent for use in magnetic resonance imaging. Invest Radiol 2001;36:401-412.
43. Gretz N, Waldherr R, Strauch M. The remnant kidney model. In: Gretz N, Strauch M, editors. Basel: Karger; 1993. p 1-28.
44. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999;99:2293-2352.
45. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006;1:128-137.
46. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22:3174-3178.
47. Wedeking P, Tweedle M. Comparison of the biodistribution of 153Gd-labeled Gd(DTPA)2-, Gd(DOTA)-, and Gd(acetate)n in mice. Int J Rad Appl Instrum B 1988;15:395-402.
48. Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging 1992;10:641-648.
49. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995;30:372-380.
50. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272-278.
51. Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol 2008;66:160-167.
52. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008;248:807-816.
53. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008;248:799-80